# Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

> **NCT01888432** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 285 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Everolimus + reduced tacrolimus
- **DRUG:** Standard tacrolimus

## Key facts

- **NCT ID:** NCT01888432
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-25
- **Primary completion:** 2016-10-19
- **Final completion:** 2018-04-21
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888432, "Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01888432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*